Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corporation    EW

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/19/2021 01/20/2021 01/21/2021 01/22/2021 01/25/2021 Date
87.91(c) 88.1(c) 87.23(c) 85.52(c) 85.89(c) Last
1 976 894 3 561 984 1 796 317 3 278 941 3 297 685 Volume
+0.05% +0.22% -0.99% -1.96% +0.43% Change
More quotes
Financials (USD)
Sales 2020 4 385 M - -
Net income 2020 819 M - -
Net cash position 2020 815 M - -
P/E ratio 2020 64,9x
Yield 2020 -
Sales 2021 5 098 M - -
Net income 2021 1 249 M - -
Net cash position 2021 1 588 M - -
P/E ratio 2021 42,6x
Yield 2021 -
Capitalization 53 531 M 53 531 M -
EV / Sales 2020 12,0x
EV / Sales 2021 10,2x
Nbr of Employees 13 900
Free-Float 97,4%
More Financials
Company
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - hemodynamic monitoring systems (61.4%); - heart valves and surgery products (20.4%); - other (18.1%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the... 
More about the company
Notations Surperformance© of Edwards Lifesciences Corporation
Trading Rating : Investor Rating :
More Ratings
All news about EDWARDS LIFESCIENCES CORPORATION
01/13EDWARDS LIFESCIENCES : To Host Earnings Conference Call On January 27, 2021
PR
2020EDWARDS LIFESCIENCES : Treats First Patient in Study Evaluating Device for Mitra..
MT
2020EDWARDS LIFESCIENCES : Treats First Patient In U.S. Clinical Trial Evaluating Mi..
PR
2020EDWARDS LIFESCIENCES' : SAPIEN 3 Valves Gets Expanded Use Approval In Canada
MT
2020EDWARDS LIFESCIENCES : SAPIEN 3 TAVI Receives Expanded Approval In Canada
AQ
2020EDWARDS LIFESCIENCES : Citigroup Downgrades Edwards Lifesciences to Neutral From..
MT
2020EDWARDS LIFESCIENCES : Goldman Sachs Adjusts Edwards Lifesciences PT to $94 From..
MT
2020EDWARDS LIFESCIENCES : Morgan Stanley Adjusts Price Target on Edwards Lifescienc..
MT
2020EDWARDS LIFESCIENCES : Stifel Nicolaus Adjusts Price Target for Edwards Lifescie..
MT
2020EDWARDS LIFESCIENCES : Oppenheimer Adjusts Edwards Lifesciences PT to $94 From $..
MT
2020EDWARDS LIFESCIENCES : SVB Leerink Adjusts Price Target on Edwards Lifesciences ..
MT
2020EDWARDS LIFESCIENCES : Piper Sandler Adjusts Price Target on Edwards Lifescience..
MT
2020EDWARDS LIFESCIENCES : Raymond James Adjusts Edwards Lifesciences' Price Target ..
MT
2020EDWARDS LIFESCIENCES : Canaccord Genuity Adjusts Price Target on Edwards Lifesci..
MT
2020EDWARDS LIFESCIENCES : UBS Adjusts Price Target on Edwards Lifesciences to $90 F..
MT
More news
News in other languages on EDWARDS LIFESCIENCES CORPORATION
01/22EDWARDS LIFESCIENCES CORPORATION : publication des résultats annuels
01/22EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Jahresergebnisses
2020EDWARDS LIFESCIENCES CORPORATION : publication des résultats trimestriels
2020EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Quartalsergebnisses
2020EDWARDS LIFESCIENCES CORPORATION : publication des résultats semestriels
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 93,43 $
Last Close Price 85,89 $
Spread / Highest target 29,2%
Spread / Average Target 8,78%
Spread / Lowest Target -25,5%
EPS Revisions
Managers and Directors
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
John P. McGrath Vice President-Quality, Regulatory & Clinical
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
William J. Link Independent Director
Sector and Competitors